Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gelcide is a locally delivered subgingival antibiotic gel formulation containing a combination of the broad-spectrum ureidopenicillin antibiotic piperacillin and the beta-lactamase inhibitor tazobactam. Developed by Italmed in collaboration with MedTechDental and investigated in clinical trials sponsored by MegaGen Dental Implant Romania, Gelcide is designed as an adjunct to non-surgical mechanical debridement (scaling and root planing) for the treatment of stage III–IV periodontitis and peri-implantitis in adults. The product is supplied as a kit containing a powder of piperacillin and tazobactam and a liquid hydroalcoholic solution, which are mixed immediately before application. Once applied subgingivally into the periodontal pocket, the mixture transitions into a bioadhesive gel that seals the pocket, protecting it from bacterial recolonization and gradually releasing the active antimicrobials over 8 to 10 days to target periodontal pathogens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on piperacillin + tazobactam (Italmed).